Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:4/15/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

To date, more than 65% of the total number of required patients have been enrolled in the Company's MAESTRO-03 clinical trial, with full enrollment anticipated for the end of the first half of 2008.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at BioCentury Conference
2. BioMS Medical Announces 2007 Year End Results
3. BioMS Medical to present at BIO CEO & Investor Conference
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medical announces third quarter 2007 results
8. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at BioContact 2007
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... 30 VEGA PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today ... Power Company, Inc. to assist the Company in building a ... Vega recently announced its intention to build a biomass plant ... materials in the State,s Bioenergy Corridor. Georgia ranks third ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of ... create a comprehensive influenza vaccine solution for the Spanish ... led by the Spanish Ministry of Health and other ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) ... Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient ... on November 6, 2006; upon publication and issuance, the ... force until November 5, 2024. This new patent strengthens ...
Cached Biology Technology:Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... February 20, 2012A team of researchers has found a ... will continue to be available, despite the potential attack ... Disease and poses a significant threat to the California ... Alamos National Laboratory (LANL), University of California at Davis ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
... has awarded The University of Texas at Austin and ... Dynamics Collaboratory (DDC), a network of researchers working to ... reliably predict the physical and ecological evolution of river ... the project, including Paola Passalacqua, assistant professor in Civil, ...
Cached Biology News:More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration 2
... The HEEBO (Human Exonic Evidence Based ... Evidence Based Oligonucleotide ) Genome Set contain ... largely derived from constitutively expressed exons, allowing ... collaboration with leading researchers at Stanford University ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: